Pharmaceutical and biotechnology companies face many challenges in discovering and developing innovative therapeutics, both in terms of resource allocation and risk management. As a company with its own proprietary pipeline, Aurigene fully understands and appreciates these challenges.
We believe our integrated approach and our ability to execute on projects from hit identification/ validation through to clinical candidate development, coupled with our experience of working with diverse scientific approaches with different partners across the world, puts us in a unique position to be able to address such challenges.
Aurigene works with established pharmaceutical and biotechnology companies in early-stage drug discovery research services partnerships, bringing drug candidates from hit generation through to development candidate stage. Our expertise in a wide range of target classes and across therapeutic areas of oncology, inflammation, metabolic disorders, anti-infective and other niche indications, our fully integrated drug discovery engine and our cost efficiency are the key value drivers for these collaborations.
- Our track-record of having executed >65 discovery programs using both small molecules and peptide approaches
- A Senior Scientific team of over 40 scientists with strong scientific and academic backgrounds and a rich drug discovery experience (>10 years at Aurigene)
- A stable Senior Management team that provides leadership and strategic oversight of these projects
All combine to provide a very distinctive advantage as a Drug Discovery partner of choice.
Over the past 10 years, Aurigene has delivered eleven (11) clinical candidates to our partners, many of which are in Phase I/ II global clinical trials.
Aurigene offers both integrated and stand-alone discovery research services